Byhealth (300146) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥6.27 billion in 2025, down 8.38% year-over-year; net profit attributable to shareholders rose 19.81% to ¥782 million.

• Main brand revenue declined, but overseas LSG brand grew 16.43% year-over-year.

• Focused on product innovation, digital transformation, and multi-channel business optimization.

• Celebrated 30th anniversary, emphasizing quality, scientific research, and international expansion.

Financial highlights

• Total assets at year-end: ¥13.98 billion, down 2.10% from previous year.

• Net assets attributable to shareholders: ¥11.11 billion, up 0.53% year-over-year.

• Operating cash flow: ¥1.21 billion, up 76.94% year-over-year.

• Basic EPS: ¥0.47, up 20.51% year-over-year.

• Proposed cash dividend: ¥4.5 per 10 shares (tax included).

Outlook and guidance

• Continued focus on core product innovation, digitalization, and international market expansion.

• Plans to strengthen brand influence and optimize channel strategies for sustainable growth.